Article
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis
Rating:
0.0
Views:
139
Likes:
1
Library:
1
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the Independent Data Monitoring Committee (IDMC) which conducted an interim analysis of the Companys Phase III Comfort„¢ trial of Piclidenoson in the treatment of moderate-to-severe plaque psoriasis, […]
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value